GW's epilepsy timetable eclipses Sativex cancer miss

Investors ignored a Phase III trial miss for Sativex in cancer pain on Thursday, pushing up shares of GW Pharmaceuticals plc (NASDAQ:GWPH; LSE:GWP) by 13% on NASDAQ after the company said it expects to begin reading out Phase III trials by year end for its Epidiolex oral liquid formulation of cannabidiol in severe, drug-resistant childhood epilepsy.

Specifically, GW said it anticipates top-line data by YE15 from at least one pivotal trial in Dravet syndrome and at least one pivotal study in Lennox-Gastaut syndrome (LGS). ...